PureBMC® SupraPhysiologic is autologous bone marrow concentrate (BMC) that’s clinically accepted modern progenitor stem cell medicine that’s used in the treatment of various pathologies. It supports tissue healing and regeneration through a cell milieu that comprises of a concentrated combination of differentiating stem cells consisting of hematopoietic, mesenchymal, and total nucleated cells, in addition to platelets and other cell mediators and cytokines.  The use of PureBMC® is a point of care minimally invasive biologic that adds the power of self-renewal and differentiation to biologic therapies for musculoskeletal pathologies, spinal disorders, chronic wound care, and critical limb ischemia and a host of other wounds and injuries.  It is an effective treatment in the rapidly growing field of regenerative medicine. PureBMC® SupraPhysiologic is the state of the art in bone marrow concentrating system that leads with biologic power, safety, efficiency and clinical outcomes.

Hematopoietic stem cells (HSCs) play a pivotal role in bone marrow concentrate (BMC) preparations, offering unparalleled regenerative potential for tissue repair and immune modulation. These multipotent cells drive the formation of new blood and immune cells, enhancing the body’s natural healing processes and promoting recovery in orthopedic, vascular, and chronic wound applications. Enriched within a well-prepared BMC, HSCs work synergistically with mesenchymal stem cells, cytokines, and growth factors to accelerate tissue regeneration while reducing inflammation. By leveraging high concentrations of HSCs in a precisely formulated BMC, physicians can optimize patient outcomes, improving healing efficiency and clinical efficacy across various regenerative therapies.

PureBMC® SupraPhysiologic is designed with advanced technology that precisely isolates and captures hematopoietic stem cells, ensuring the highest possible concentrations for superior regenerative potential. Its innovative processing system optimizes cell recovery while minimizing free hemoglobin, delivering a potent and pure BMC formulation that enhances healing and clinical outcomes.

Mesenchymal stem cells (MSCs) in bone marrow concentrate play a critical role in regenerative healing due to their ability to differentiate into key tissue types such as bone, cartilage, and fat. Although MSCs make up only a small fraction of the total cell population in bone marrow aspirate—approximately 0.001% to 0.01%—their biological significance is profound, as they contribute to tissue repair, modulate inflammation, and support cellular regeneration. By concentrating bone marrow, the therapeutic potential of MSCs is enhanced, optimizing their availability and effectiveness in clinical applications. This enriched environment not only improves regenerative outcomes but also provides a more potent and versatile treatment option for musculoskeletal and orthopedic conditions.

The role of red blood cells (RBCs) in its formulation has been a subject of ongoing refinement. Excess RBC content in PRP formulations has been associated with pro-inflammatory effects, oxidative stress, and potential cytotoxicity, all of which can impede the regenerative process. The breakdown of RBCs leads to the release of hemoglobin and iron, which can contribute to oxidative damage and inflammation factors that may counteract the healing benefits of PRP. By reducing the RBC concentration, clinicians can mitigate these adverse effects, creating a more favorable microenvironment for tissue repair. However, the complete elimination of RBCs from PRP is not necessarily required. A minimal presence of RBCs at low levels does not exert a deleterious effect on tissue healing. In fact, trace amounts of RBCs may play a supportive role by maintaining physiological oxygen levels in the local tissue environment, which can be beneficial for cellular metabolism and angiogenesis.